Ray Dalio's HAE Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 48,377 shares of Haemonetics Corporation (HAE) worth $2.73 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 48,377 shares. Largest reduction occurred in Q4 2025, reducing 59,104 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +48,377 | New Buy | 48,377 | $56.36 |
| Q4 2025 | -59,104 | Sold Out | 0 | $0.00 |
| Q3 2025 | +12,820 | Add 27.70% | 59,104 | $48.74 |
| Q2 2025 | +24,764 | Add 115.07% | 46,284 | $74.61 |
| Q1 2025 | +16,128 | Add 299.11% | 21,520 | $63.55 |
| Q4 2024 | -2,434 | Reduce 31.10% | 5,392 | $78.08 |
| Q3 2024 | -35,747 | Reduce 82.04% | 7,826 | $80.38 |
| Q2 2024 | -3,206 | Reduce 6.85% | 43,573 | $82.73 |
| Q1 2024 | -7,960 | Reduce 14.54% | 46,779 | $85.35 |
| Q4 2023 | -5,413 | Reduce 9.00% | 54,739 | $85.51 |
| Q3 2023 | +4,957 | Add 8.98% | 60,152 | $89.58 |
| Q2 2023 | -6,434 | Reduce 10.44% | 55,195 | $85.14 |
| Q1 2023 | +2,102 | Add 3.53% | 61,629 | $82.75 |
| Q4 2022 | -21,454 | Reduce 26.49% | 59,527 | $78.65 |
| Q3 2022 | -64 | Reduce 0.08% | 80,981 | $74.03 |
| Q2 2022 | +7,552 | Add 10.28% | 81,045 | $65.19 |
| Q1 2022 | +17,518 | Add 31.30% | 73,493 | $63.22 |
| Q4 2021 | +8,306 | Add 17.42% | 55,975 | $53.04 |
| Q3 2021 | -4,236 | Reduce 8.16% | 47,669 | $70.59 |
| Q2 2021 | +51,905 | New Buy | 51,905 | $66.64 |
Ray Dalio's Haemonetics Corporation Investment FAQs
Ray Dalio first purchased Haemonetics Corporation (HAE) in Q2 2021, acquiring 51,905 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Haemonetics Corporation (HAE) for 20 quarters since Q2 2021.
Ray Dalio's largest addition to Haemonetics Corporation (HAE) was in Q2 2021, adding 51,905 shares worth $3.46 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 48,377 shares of Haemonetics Corporation (HAE), valued at approximately $2.73 M.
As of the Q1 2026 filing, Haemonetics Corporation (HAE) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Haemonetics Corporation (HAE) was 81,045 shares, as reported at the end of Q2 2022.